Phase 2a study of readthrough therapy in nonsense mutation Alport syndrome
Journal of Clinical Investigation · 12.11.2026
DOI: 10.1172/jci208623 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 12.11.2026. Verfasst von Daniel P Gale und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, University College London, London, United Kingdom. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health, Stoneygate Trust and Kidney Research UK, Eloxx Pharmaceuticals Inc.
Abstract (Originalsprache)
BACKGROUND. Alport syndrome (AS), a Mendelian kidney disease, is caused by pathogenic mutations in the X- linked gene COL4A5 and autosomal genes COL4A3 , COL4A4 encoding the alpha-chains secreted by podocytes to form the glomerular basement membrane collagen α3α4α5(IV) trimer. Nonsense mutations in autosomal recessive and hemizygous X-linked Alport syndrome (NMAS) introduce premature termination codons and have a particularly poor prognosis, with kidney failure typically occurring by early adulthood. There is substantial unmet need for effective therapy for AS, which has no approved treatments. Exaluren (formerly ELX-02) is a novel eukaryotic ribosome-targeted glycoside that is preferentially taken up by kidney cells and promotes readthrough of premature but not native termination codons, allowing full-length protein production. METHODS. In this proof-of-mechanism study, three patients (ages 12–18) with autosomal recessive Alport syndrome and a COL4A4 premature termination codon received daily subcutaneous exaluren (0.75 mg/kg) for 8 weeks. RESULTS. Safety and tolerability assessments (primary endpoint) revealed no new signals. Secondary endpoints assessed by kidney biopsy before and after treatment revealed increased collagen α3(IV), α4(IV) and α5(IV) abundance, physiologically localised collagen α5(IV), and partially improved podocyte morphology in all participants, with changes directionally concordant with increased collagen α3α4(IV) abundance. Proteinuria changes were inconsistent with interpretation limited by intra-patient variability and the short treatment duration; hematuria persisted in all participants. CONCLUSION. These findings provide first-in-human evidence of exaluren-mediated collagen IV readthrough and justify further trials in Alport syndrome and other nonsense mutation-driven kidney diseases, which often cause early-onset kidney failure. TRIAL REGISTRATION. ClinicalTrials.gov Identifier: NCT05448755.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Renal Medicine, University College London, London, United Kingdom.
- Manchester Cell-Matrix Centre, The University of Manchester, Manchester, United Kingdom.
- Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, United States of America.
- Eloxx Pharmaceuticals Inc., Watertown, United States of America.
- University of Texas Medical Branch, Galveston, United States of America.
- Wyss Center for Bio and Neuroengineering, Boston, United States of America.
Förderung
- National Institutes of Health
- Stoneygate Trust and Kidney Research UK
- Eloxx Pharmaceuticals Inc
Zitieren
APA
Gale, D. P., Böckenhauer, D., Fresquet, M., Williams, E., Sugden, C. J., Chan, M. M., Wong, K., Lin, M. H., Omachi, K., Tzoumkas, K., Horonchik, L., Clark, R. B., Reiser, J., Mundel, P., Andag, U., Miner, J. H., Lennon, R., Endlich, N., Najafian, B., & Aggarwal, S. (2026). Phase 2a study of readthrough therapy in nonsense mutation Alport syndrome. Journal of Clinical Investigation. https://doi.org/10.1172/jci208623
Vancouver
Gale DP, Böckenhauer D, Fresquet M, Williams E, Sugden CJ, Chan MM, et al. Phase 2a study of readthrough therapy in nonsense mutation Alport syndrome. Journal of Clinical Investigation. 2026. doi:10.1172/jci208623
BibTeX
@article{Gale2026,
author = {Gale, Daniel P and Böckenhauer, Detlef and Fresquet, Maryline and Williams, Emily and Sugden, Conor J and Chan, Melanie My and Wong, Katie and Lin, Meei-Hua and Omachi, Kohei and Tzoumkas, Konstantinos and Horonchik, Lior and Clark, Roger B and Reiser, Jochen and Mundel, Peter and Andag, Uwe and Miner, Jeffrey H and Lennon, Rachel and Endlich, Nicole and Najafian, Behzad and Aggarwal, Sumit},
title = {Phase 2a study of readthrough therapy in nonsense mutation Alport syndrome},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci208623}
}
EUVIMED